Soligenix, Inc. (LON:0A6I)
1.370
+0.020 (1.48%)
At close: Nov 5, 2025
Soligenix Revenue
In the year 2024, Soligenix had annual revenue of $119.37K USD, down -85.78%.
Revenue
$119.37K
Revenue Growth
-85.78%
P/S Ratio
n/a
Revenue / Employee
$7.46K
Employees
16
Market Cap
8.84M GBP
Revenue Chart
* This company reports financials in USD.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 119.37K | -719.99K | -85.78% |
| Dec 31, 2023 | 839.36K | -109.55K | -11.55% |
| Dec 31, 2022 | 948.91K | 124.64K | 15.12% |
| Dec 31, 2021 | 824.27K | -1.54M | -65.07% |
| Dec 31, 2020 | 2.36M | -2.27M | -49.04% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Shell | 200.18B |
| BP p.l.c. | 138.32B |
| Unilever | 51.24B |
| HSBC Holdings | 43.13B |
| AstraZeneca | 41.24B |
| Rio Tinto Group | 39.22B |
| GSK plc | 32.17B |
| British American Tobacco p.l.c. | 25.60B |
Soligenix News
- 22 days ago - Soligenix Updates United States Medical Advisory Board for Cutaneous T-Cell Lymphoma - PRNewsWire
- 4 weeks ago - Soligenix (SNGX) Advances Phase 3 CTCL Study with Positive Safety Review - GuruFocus
- 4 weeks ago - Soligenix Achieves Important Safety Milestone in its Confirmatory Phase 3 Clinical Trial of HyBryte™ for the Treatment of Cutaneous T-Cell Lymphoma - PRNewsWire
- 4 weeks ago - Insider Buying: Christopher Schaber Acquires Shares of Soligenix Inc (SNGX) - GuruFocus
- 5 weeks ago - Soligenix Announces Expansion of European Medical Advisory Board for Cutaneous T-Cell Lymphoma - PRNewsWire
- 5 weeks ago - Soligenix Announces Closing of $7.5 Million Public Offering - PRNewsWire
- 5 weeks ago - Soligenix (SNGX) Launches Public Offering to Raise $7.5 Million - GuruFocus
- 5 weeks ago - Soligenix Prices 7.5 Mln Public Offering At $1.35/shr; Stock Up In Pre-market - Nasdaq